Daiichi Sankyo

ASCO22: Enhertu aces key HER2-low test in breast cancer
Pharmaforum
Mon, 06/6/22 - 09:43 am
ASCO 2022
AstraZeneca
Daiichi Sankyo
Enhertu
HER2-low breast cancer
breast cancer
Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges
Endpoints
Tue, 05/31/22 - 10:39 am
AstraZeneca
insider trading
SEC
Enhertu
Daiichi Sankyo
The 12 Top Biotech Companies Hiring Now
BioSpace
Tue, 05/10/22 - 10:26 pm
biotech
life sciences
hirings
Regeneron
Pfizer
Amgen
AbbVie
Moderna Therapeutics
CSL Behring
Waters Corporation
Daiichi Sankyo
Gilead Sciences
Grail
Emergent BioSolutions
resilience
FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer
Contract Pharma
Thu, 05/5/22 - 10:40 am
AstraZeneca
Daiichi Sankyo
Enhertu
FDA
HER2+ breast cancer
breast cancer
FDA starts speedy review of Enhertu in lung cancer
Pharmaforum
Tue, 04/19/22 - 10:54 am
AstraZeneca
Daiichi Sankyo
FDA
non-small cell lung cancer
Enhertu
Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo
Fierce Pharma
Mon, 04/11/22 - 11:00 am
Seagen
Daiichi Sankyo
patents
breast cancer
Enhertu
Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial
Pharmaforum
Mon, 02/21/22 - 10:35 am
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
HER2-low breast cancer
breast cancer
Daiichi makes play for share of Japan’s COVID booster market
Pharmaforum
Mon, 01/31/22 - 10:49 am
Daiichi Sankyo
COVID-19
vaccines
MRNA
Japan
DS-5670
Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development
Endpoints
Wed, 01/12/22 - 11:26 pm
Daiichi Sankyo
Plexxikon
Enhertu
Biopharma developments over the Christmas period
EP Vantage
Mon, 01/3/22 - 10:26 am
Alnylam Pharmaceuticals
Bio-Thera Solutions
BioArctic
Biogen
BridgeBio Pharma
Daiichi Sankyo
Eisai
JNJ
Madrigal Pharmaceuticals
Merck
Sutro BioPharma
Tasly Pharmaceutical Group
FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag
Pharmaforum
Thu, 12/23/21 - 11:53 am
Daiichi Sankyo
FDA
antibody-drug conjugate
lung cancer
HER3
patritumab deruxtecan
AZ, Daiichi take aim at Gilead in triple-negative breast cancer
Pharmaforum
Wed, 12/8/21 - 10:37 am
AstraZeneca
Daiichi Sankyo
Gilead Sciences
Trodelvy
triple negative breast cancer
Dato-DXd
Daiichi could be rewarded for persisting with Vanflyta
EP Vantage
Fri, 11/19/21 - 10:49 am
Daiichi Sankyo
Vanflyta
AML
Daiichi jettisons ADC after flunking early solid tumor test
Fierce Biotech
Fri, 10/29/21 - 10:34 am
Daiichi Sankyo
antibody-drug conjugate
GIST
DS-6157
solid tumors
Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio
BioSpace
Tue, 10/26/21 - 12:01 am
Merck
Keytruda
Xeris Biopharma
XeriJect
Evaxion Biotech
EVX-01
Daiichi Sankyo
AstraZeneca
datopotamab deruxtecan
Enhertu nabs speedy FDA review for earlier use in breast cancer
Pharmaforum
Mon, 10/4/21 - 10:57 am
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
FDA
ESMO 2021 movers – a handful of biotech winners emerge
EP Vantage
Fri, 09/24/21 - 11:48 am
ESMO
Corbus Pharmaceuticals
Leap Therapeutics
Surface Oncology
AstraZeneca
Innate Pharma
Immunocore
Daiichi Sankyo
Verastem
Spectrum Pharrmaceuticals
Mirati Therapeutics
AstraZeneca, Daiichi Sankyo's ADC Enhertu blows away Roche's Kadcyla in second-line advanced breast cancer
Endpoints
Sat, 09/18/21 - 08:34 pm
ESMO
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
Roche
ESMO: Daiichi unveils first early peek at next-gen ADC as analysts see strong data against rivals
Fierce Biotech
Fri, 09/17/21 - 11:06 am
ESMO
Daiichi Sankyo
antibody-drug conjugate
DS-7300
AstraZeneca and Daiichi Sankyo continue to flesh out Enhertu plans, claiming win in earlier breast cancer line
Endpoints
Mon, 08/9/21 - 10:55 am
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer

Pages